Phosphorylation of the ryanodine receptor 2 at serine 2030 is required for a complete β-adrenergic response

Duilio M. Potenza, Radoslav Janicek, Miguel Fernandez-Tenorio, Emmanuel Camors, Roberto Ramos-Mondragón, Héctor H. Valdivia, Ernst Niggli

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

During physical exercise or stress, the sympathetic system stimulates cardiac contractility via β-adrenergic receptor (β-AR) activation, resulting in protein kinase A (PKA)-mediated phosphorylation of the cardiac ryanodine receptor RyR2. PKAdependent "hyperphosphorylation" of the RyR2 channel has been proposed as a major impairment that contributes to progression of heart failure. However, the sites of PKA phosphorylation and their phosphorylation status in cardiac diseases are not well defined. Among the known RyR2 phosphorylation sites, serine 2030 (S2030) remains highly controversial as a site of functional impact. We examined the contribution of RyR2-S2030 to Ca 2+ signaling and excitation-contraction coupling (ECC) in a transgenic mouse with an ablated RyR2-S2030 phosphorylation site (RyR2-S2030A+/+). We assessed ECC gain by using whole-cell patch-clamp recordings and confocal Ca 2+ imaging during β-ARs stimulation with isoproterenol (Iso) and consistent SR Ca 2+ loading and L-type Ca 2+ current (I Ca ) triggering. Under these conditions, ECC gain is diminished in mutant compared with WT cardiomyocytes. Resting Ca 2+ spark frequency (CaSpF) with Iso is also reduced by mutation of S2030. In permeabilized cells, when SR Ca 2+ pump activity is kept constant (using 2D12 antibody against phospholamban), cAMP does not change CaSpF in S2030A+/+ myocytes. Using Ca 2+ spark recovery analysis, we found that mutant RyR Ca 2+ sensitivity is not enhanced by Iso application, contrary to WT RyRs. Furthermore, ablation of RyR2-S2030 prevents acceleration of Ca 2+ waves and increases latency to the first spontaneous Ca 2+ release after a train of stimulations during Iso treatment. Together, these results suggest that phosphorylation at S2030 may represent an important step in the modulation of RyR2 activity during β-adrenergic stimulation and a potential target for the development of new antiarrhythmic drugs.

Original languageEnglish (US)
Pages (from-to)131-145
Number of pages15
JournalJournal of General Physiology
Volume151
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Ryanodine Receptor Calcium Release Channel
Adrenergic Agents
Serine
Phosphorylation
Isoproterenol
Excitation Contraction Coupling
Cyclic AMP-Dependent Protein Kinases
Anti-Arrhythmia Agents
Cardiac Myocytes
Adrenergic Receptors
Muscle Cells
Transgenic Mice
Heart Diseases
Heart Failure
Exercise
Mutation
Antibodies

All Science Journal Classification (ASJC) codes

  • Physiology

Cite this

Potenza, D. M., Janicek, R., Fernandez-Tenorio, M., Camors, E., Ramos-Mondragón, R., Valdivia, H. H., & Niggli, E. (2019). Phosphorylation of the ryanodine receptor 2 at serine 2030 is required for a complete β-adrenergic response. Journal of General Physiology, 151(2), 131-145. https://doi.org/10.1085/jgp.201812155

Phosphorylation of the ryanodine receptor 2 at serine 2030 is required for a complete β-adrenergic response. / Potenza, Duilio M.; Janicek, Radoslav; Fernandez-Tenorio, Miguel; Camors, Emmanuel; Ramos-Mondragón, Roberto; Valdivia, Héctor H.; Niggli, Ernst.

In: Journal of General Physiology, Vol. 151, No. 2, 01.02.2019, p. 131-145.

Research output: Contribution to journalArticle

Potenza, DM, Janicek, R, Fernandez-Tenorio, M, Camors, E, Ramos-Mondragón, R, Valdivia, HH & Niggli, E 2019, 'Phosphorylation of the ryanodine receptor 2 at serine 2030 is required for a complete β-adrenergic response', Journal of General Physiology, vol. 151, no. 2, pp. 131-145. https://doi.org/10.1085/jgp.201812155
Potenza, Duilio M. ; Janicek, Radoslav ; Fernandez-Tenorio, Miguel ; Camors, Emmanuel ; Ramos-Mondragón, Roberto ; Valdivia, Héctor H. ; Niggli, Ernst. / Phosphorylation of the ryanodine receptor 2 at serine 2030 is required for a complete β-adrenergic response. In: Journal of General Physiology. 2019 ; Vol. 151, No. 2. pp. 131-145.
@article{ff99ed5fb44a4defa823bf5d6518d1e8,
title = "Phosphorylation of the ryanodine receptor 2 at serine 2030 is required for a complete β-adrenergic response",
abstract = "During physical exercise or stress, the sympathetic system stimulates cardiac contractility via β-adrenergic receptor (β-AR) activation, resulting in protein kinase A (PKA)-mediated phosphorylation of the cardiac ryanodine receptor RyR2. PKAdependent {"}hyperphosphorylation{"} of the RyR2 channel has been proposed as a major impairment that contributes to progression of heart failure. However, the sites of PKA phosphorylation and their phosphorylation status in cardiac diseases are not well defined. Among the known RyR2 phosphorylation sites, serine 2030 (S2030) remains highly controversial as a site of functional impact. We examined the contribution of RyR2-S2030 to Ca 2+ signaling and excitation-contraction coupling (ECC) in a transgenic mouse with an ablated RyR2-S2030 phosphorylation site (RyR2-S2030A+/+). We assessed ECC gain by using whole-cell patch-clamp recordings and confocal Ca 2+ imaging during β-ARs stimulation with isoproterenol (Iso) and consistent SR Ca 2+ loading and L-type Ca 2+ current (I Ca ) triggering. Under these conditions, ECC gain is diminished in mutant compared with WT cardiomyocytes. Resting Ca 2+ spark frequency (CaSpF) with Iso is also reduced by mutation of S2030. In permeabilized cells, when SR Ca 2+ pump activity is kept constant (using 2D12 antibody against phospholamban), cAMP does not change CaSpF in S2030A+/+ myocytes. Using Ca 2+ spark recovery analysis, we found that mutant RyR Ca 2+ sensitivity is not enhanced by Iso application, contrary to WT RyRs. Furthermore, ablation of RyR2-S2030 prevents acceleration of Ca 2+ waves and increases latency to the first spontaneous Ca 2+ release after a train of stimulations during Iso treatment. Together, these results suggest that phosphorylation at S2030 may represent an important step in the modulation of RyR2 activity during β-adrenergic stimulation and a potential target for the development of new antiarrhythmic drugs.",
author = "Potenza, {Duilio M.} and Radoslav Janicek and Miguel Fernandez-Tenorio and Emmanuel Camors and Roberto Ramos-Mondrag{\'o}n and Valdivia, {H{\'e}ctor H.} and Ernst Niggli",
year = "2019",
month = "2",
day = "1",
doi = "10.1085/jgp.201812155",
language = "English (US)",
volume = "151",
pages = "131--145",
journal = "Journal of General Physiology",
issn = "0022-1295",
publisher = "Rockefeller University Press",
number = "2",

}

TY - JOUR

T1 - Phosphorylation of the ryanodine receptor 2 at serine 2030 is required for a complete β-adrenergic response

AU - Potenza, Duilio M.

AU - Janicek, Radoslav

AU - Fernandez-Tenorio, Miguel

AU - Camors, Emmanuel

AU - Ramos-Mondragón, Roberto

AU - Valdivia, Héctor H.

AU - Niggli, Ernst

PY - 2019/2/1

Y1 - 2019/2/1

N2 - During physical exercise or stress, the sympathetic system stimulates cardiac contractility via β-adrenergic receptor (β-AR) activation, resulting in protein kinase A (PKA)-mediated phosphorylation of the cardiac ryanodine receptor RyR2. PKAdependent "hyperphosphorylation" of the RyR2 channel has been proposed as a major impairment that contributes to progression of heart failure. However, the sites of PKA phosphorylation and their phosphorylation status in cardiac diseases are not well defined. Among the known RyR2 phosphorylation sites, serine 2030 (S2030) remains highly controversial as a site of functional impact. We examined the contribution of RyR2-S2030 to Ca 2+ signaling and excitation-contraction coupling (ECC) in a transgenic mouse with an ablated RyR2-S2030 phosphorylation site (RyR2-S2030A+/+). We assessed ECC gain by using whole-cell patch-clamp recordings and confocal Ca 2+ imaging during β-ARs stimulation with isoproterenol (Iso) and consistent SR Ca 2+ loading and L-type Ca 2+ current (I Ca ) triggering. Under these conditions, ECC gain is diminished in mutant compared with WT cardiomyocytes. Resting Ca 2+ spark frequency (CaSpF) with Iso is also reduced by mutation of S2030. In permeabilized cells, when SR Ca 2+ pump activity is kept constant (using 2D12 antibody against phospholamban), cAMP does not change CaSpF in S2030A+/+ myocytes. Using Ca 2+ spark recovery analysis, we found that mutant RyR Ca 2+ sensitivity is not enhanced by Iso application, contrary to WT RyRs. Furthermore, ablation of RyR2-S2030 prevents acceleration of Ca 2+ waves and increases latency to the first spontaneous Ca 2+ release after a train of stimulations during Iso treatment. Together, these results suggest that phosphorylation at S2030 may represent an important step in the modulation of RyR2 activity during β-adrenergic stimulation and a potential target for the development of new antiarrhythmic drugs.

AB - During physical exercise or stress, the sympathetic system stimulates cardiac contractility via β-adrenergic receptor (β-AR) activation, resulting in protein kinase A (PKA)-mediated phosphorylation of the cardiac ryanodine receptor RyR2. PKAdependent "hyperphosphorylation" of the RyR2 channel has been proposed as a major impairment that contributes to progression of heart failure. However, the sites of PKA phosphorylation and their phosphorylation status in cardiac diseases are not well defined. Among the known RyR2 phosphorylation sites, serine 2030 (S2030) remains highly controversial as a site of functional impact. We examined the contribution of RyR2-S2030 to Ca 2+ signaling and excitation-contraction coupling (ECC) in a transgenic mouse with an ablated RyR2-S2030 phosphorylation site (RyR2-S2030A+/+). We assessed ECC gain by using whole-cell patch-clamp recordings and confocal Ca 2+ imaging during β-ARs stimulation with isoproterenol (Iso) and consistent SR Ca 2+ loading and L-type Ca 2+ current (I Ca ) triggering. Under these conditions, ECC gain is diminished in mutant compared with WT cardiomyocytes. Resting Ca 2+ spark frequency (CaSpF) with Iso is also reduced by mutation of S2030. In permeabilized cells, when SR Ca 2+ pump activity is kept constant (using 2D12 antibody against phospholamban), cAMP does not change CaSpF in S2030A+/+ myocytes. Using Ca 2+ spark recovery analysis, we found that mutant RyR Ca 2+ sensitivity is not enhanced by Iso application, contrary to WT RyRs. Furthermore, ablation of RyR2-S2030 prevents acceleration of Ca 2+ waves and increases latency to the first spontaneous Ca 2+ release after a train of stimulations during Iso treatment. Together, these results suggest that phosphorylation at S2030 may represent an important step in the modulation of RyR2 activity during β-adrenergic stimulation and a potential target for the development of new antiarrhythmic drugs.

UR - http://www.scopus.com/inward/record.url?scp=85059802803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059802803&partnerID=8YFLogxK

U2 - 10.1085/jgp.201812155

DO - 10.1085/jgp.201812155

M3 - Article

C2 - 30541771

AN - SCOPUS:85059802803

VL - 151

SP - 131

EP - 145

JO - Journal of General Physiology

JF - Journal of General Physiology

SN - 0022-1295

IS - 2

ER -